Efficacy and Safety of Gamma Ventral Capsulotomy for Treatment-Resistant Obsessive-Compulsive Disorder: A Single-Center Experience

Basit Öğe Kaydı
dc.authoridPeker, Selcuk/0000-0003-3057-3355|Samanci, Yavuz/0000-0001-8952-6866
dc.authorwosidPeker, Selcuk/D-2516-2015
dc.authorwosidPeker, Selcuk/JBJ-5917-2023
dc.authorwosidSamanci, Yavuz/I-1408-2016
dc.contributor.authorPeker, Selcuk
dc.contributor.authorSamanci, Mustafa Yavuz
dc.contributor.authorYilmaz, Meltem
dc.contributor.authorSengoz, Meric
dc.contributor.authorUlku, Nazan
dc.contributor.authorOgel, Kultegin
dc.date.accessioned2024-07-18T20:56:07Z
dc.date.available2024-07-18T20:56:07Z
dc.date.issued2020
dc.departmentİstanbul Bilgi Üniversitesien_US
dc.description.abstractBACKGROUND: Obsessive-compulsive disorder (OCD) is a chronic disease with a lifetime prevalence of 3% and is associated with severe impairment in familial and socio-occupational functioning. Gamma ventral capsulotomy (GVC) is a treatment choice in carefully chosen patients, with few published reports. In this study, we aimed to report the efficacy and safety of GVC in 21 patients with treatment-resistant OCD. METHODS: This is a retrospective single-center study. Twenty-one patients meeting the selection criteria were included. Patients were considered responders if there were >= 35% reduction in post-GVC Yale-Brown Obsessive Compulsive Scale scores and considered in remission if scores were <= 8. The mean and median clinical follow-up durations were 60.7 and 56 months, respectively (range, 38-149 months). RESULTS: The mean baseline Yale-Brown Obsessive Compulsive Scale score of 35.7 (n = 21) decreased to 15.3 (n = 20) at 36 months follow-up evaluation (P < 0.0001). Fifteen patients (75%) achieved a full response. Of those patients, 7 (35%) were considered to be in remission. There were no partial responders, and 5 patients (25%) were classified as nonresponders. The pre-GVC mean Beck Depression Inventory-II score of 35.1 (n = 21) decreased to 13.8 (n = 20) at 36 months follow-up evaluation (P < 0.0001). Three patients (14.3%) had a transient post-GVC headache that resolved within a week, and 2 patients (9.5%) had persistent headaches that responded to 2-week oral corticosteroid treatment. A brain cyst developed after GVC in 2 patients (10%). No clinically notable abnormalities were seen on neurologic examination at any follow-up. CONCLUSIONS: Gamma ventral capsulotomy is a reasonable treatment method in select patients with treatment-resistant OCD.en_US
dc.identifier.doi10.1016/j.wneu.2020.06.098
dc.identifier.endpageE952en_US
dc.identifier.issn1878-8750
dc.identifier.issn1878-8769
dc.identifier.pmid32565377en_US
dc.identifier.scopus2-s2.0-85088120630en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpageE941en_US
dc.identifier.urihttps://doi.org/10.1016/j.wneu.2020.06.098
dc.identifier.urihttps://hdl.handle.net/11411/8871
dc.identifier.volume141en_US
dc.identifier.wosWOS:000564383400032en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofWorld Neurosurgeryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGamma Ventral Capsulotomyen_US
dc.subjectObsessive-Compulsive Disorderen_US
dc.subjectY-Bocsen_US
dc.subjectTerm-Follow-Upen_US
dc.subjectDeep Brain-Stimulationen_US
dc.subjectNeurosurgical Treatmenten_US
dc.subjectAnxiety Disordersen_US
dc.titleEfficacy and Safety of Gamma Ventral Capsulotomy for Treatment-Resistant Obsessive-Compulsive Disorder: A Single-Center Experience
dc.typeArticle

Dosyalar

Koleksiyon

Web of Science Indexed Publications
PubMed Indexed Publications
Scopus Indexed Publications

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our about.

Customize